Target species
Cattle (pre-ruminant cattle), pigs
Indications for use, specifying the target species
Treatment of gastro-intestinal infections caused by Escherichia coli susceptible to paromomycin.
Contraindications
Do not use in animals with known hypersensitivity to paromomycin, other aminoglycosides or any of the excipients.
Do not use in cases with impaired function of the kidneys or liver.
Do not use in ruminating animals.
Do not use in turkeys due to the risk of selection for antimicrobial resistance in intestinal bacteria.
Special warnings for each target species
None.
Special precautions for use
Special precautions for use in animals
The uptake of medication by animals can be altered as a consequence of illness. In case of insufficient uptake of water/milk animals should be treated parenterally using a suitable injectable product following the advice of the veterinarian.
The use of the product should be combined with good management practices e.g. good hygiene, proper ventilation, no overstocking.
Since the product is potentially ototoxic and nephrotoxic, it is recommended to assess kidney function. Special care should be taken when considering administration of the product to newborn animals due to the known higher gastrointestinal absorption of paromomycin in neonates. This higher absorption could lead to an increased risk of oto-and nephrotoxicity. The use of the product in neonates should be based on benefit-risk assessment by the responsible veterinarian.
Prolonged or repeated use of the product should be avoided by improving management practices and through cleansing and disinfection. Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Official, national and regional antimicrobial policies should be taken into account when the product is used.
Use of the product deviating from the given instructions may increase the prevalence of bacteria resistant to paromomycin and may decrease the effectiveness of treatment with aminoglycosides due to the potential for cross-resistance.
Aminoglycosides are considered as critical in human medicine. Consequently, they should not be used as a first intention treatment in veterinary medicine.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
- This product contains paromomycin, which can cause allergic reactions in some people.
- People with known hypersensitivity (allergy) to paromomycin or any other aminoglycosides should avoid contact with the product.
- Avoid contact with the skin and eyes.
- Personal protective equipment consisting of protective clothing and impervious gloves should be worn when handling the product.
- In the event of accidental contact with the skin or eyes, rinse with plenty of water.
- If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the physician this warning. Swelling of the face, lips and eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.
- Do not eat, drink and smoke when handling the product.
- Do not ingest. In case of accidental ingestion, seek medical advice immediately and show the label to the physician.
- Wash hands after use.
Adverse reactions (frequency and seriousness)
In rare occasions soft faeces has been observed.
Aminoglycoside antibiotics such as paromomycin can cause oto- and nephrotoxicity.
Use during pregnancy, lactation or lay
Laboratory studies in the rat and rabbit have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. The use is not recommended during pregnancy.
Interaction with other medicinal products and other forms of interaction
General anaesthetics and muscle relaxing products increase the neuro-blocking effect of aminoglycosides. This may cause paralysis and apnoea.
Do not use concurrently with strong diuretics and potentially oto- or nephrotoxic substances.
Amounts to be administered and administration route
Oral use.
Pre-ruminant cattle: administration in milk/milk replacer.
Pigs: administration in drinking water.
Duration of treatment: 3-5 days.
Pre-ruminant cattle 1.25 – 2.5 ml of product/10 kg BW/day, equivalent to 17500 - 35000 IU of paromomycin per kg BW/day (i.e. approximately 25-50 mg paromomycin sulfate per kg BW/day).
Pigs: 1.25 – 2 ml of product/10 kg BW/day, equivalent to 17500 - 28000 IU of paromomycin per kg BW/day (i.e. approximately 25-40 mg paromomycin sulfate per kg BW/day).
For the administration through the drinking water the exact daily amount of product should be based on the number of the animals to be treated, and the recommended dose calculated according to the following formula:
ml product/kg BW/day x Mean bodyweight (kg) of animals to be treated | = ml product per litre drinking water/day/animal |
_______________________________________________________ |
Mean daily water consumption (litre) per animal |
To ensure a correct dosage bodyweight should be determined as accurately as possible.
The uptake of medicated water depends on several factors including clinical conditions of the animals and the local conditions such as ambient temperature and humidity. In order to obtain the correct dosage, uptake of drinking water has to be monitored and the concentration of paromomycin has to be adjusted accordingly.
Medicated drinking water/milk/milk replacer and any stock solutions should be freshly prepared every 6 hours (in milk/milk replacer) or every 24 hours (in water).
Overdose (symptoms, emergency procedures, antidotes), if necessary
Paromomycin when administered orally is hardly absorbed systemically. Harmful effects due to accidental overdosing are highly unlikely.
Withdrawal period(s)
Cattle:
Meat and offal: 20 days
Pigs:
Meat and offal: 3 days